Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, 2-Part, Single Ascending Dose Assessment of the Safety, Tolerability, and Pharmacokinetics of Rolapitant Intravenous in Healthy Volunteers

NCT02382666 is registered in ClinicalTrials.gov with Tesaro, Inc. as lead sponsor.

NCT NCT02382666
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02382666 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, 2-Part, Single Ascending Dose Assessment of the Safety, Tolerability, and Pharmacokinetics of Rolapitant Intravenous in Healthy Volunteers
Lead sponsor
Tesaro, Inc.
Phase
Phase 1
Overall status
Completed
Start date
January 31, 2015
Completion date
August 31, 2015
Enrollment
100 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chemotherapy-induced nausea and vomiting